肺动脉高压的治疗进展  

New progress in treatment of pulmonary hypertension

作　　者：李晓晨[1,2] 黄玉臣 刘先胜 LI Xiao-chen;HUANG Yu-chen;LIU Xian-sheng(Department of Pulmonary and Critical Care Medicine,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Hubei Wuhan 430030,China;Key Laboratory of Pulmonary Diseases of National Health Commission,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Hubei Wuhan 430030,China;Shanxi Bethune Hospital,Shanxi Taiyuan 030032,China)

机构地区：[1]华中科技大学同济医学院附属同济医院呼吸与危重症医学科,湖北武汉430030 [2]国家卫健委呼吸系统疾病重点实验室,湖北武汉430030 [3]山西白求恩医院(山西医学科学院)同济山西医院呼吸与危重症医学科,山西太原030032

出　　处：《内科急危重症杂志》2024年第5期385-390,共6页Journal of Critical Care In Internal Medicine

基　　金：国家自然科学基金(81973987)。

摘　　要：肺动脉高压(PH)是指由多种异源性疾病(病因)和不同发病机制所致肺血管结构或功能改变,引起肺血管阻力和肺动脉压力升高的临床和病理生理综合征,继而发展成右心衰竭甚至死亡。PH是一个重大的全球健康问题,所有年龄段的人群均可发生PH。临床实践中,PH的治疗和管理具有复杂性、异质性、专业性的特点,需要医患共同决策的全方位、整体化、多学科的策略。本文将结合最新国内外指南及高质量临床研究和真实世界数据总结PH的治疗进展。Pulmonary hypertension(PH)is a clinical and pathophysiologic syndrome of elevated pulmonary vascular resistance and pulmonary arterial pressure due to structural or functional changes in the pulmonary vasculature caused by a variety of heterogenic diseases(etiology)and different pathogenic mechanisms,followed by the development of right heart failure or even death.PH is a major global health problem,and it can occur in people of all ages.In clinical practice,the treatment and management of PH is characterized by complexity,heterogeneity,and specialization,and requires an all-encompassing,holistic,and multidisciplinary strategy of shared decision-making between doctors and patients.This article summarizes the advances in the treatment of PH in the light of the latest national and international guidelines and high-quality clinical studies and real-world data.

关 键 词：肺动脉高压 治疗 决策 

分 类 号：R544.16[医药卫生—心血管疾病]